Completed PHASE2 INTERVENTIONAL 1-arm NCT01610180

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Sponsor: Fondazione Progetto Ematologia

Conditions Autoimmune Thrombocytopenia Autoimmune Thrombocytopenic Purpura Chronic Lymphocytic Leukemia Non Hodgkin's Lymphoma Purpura, Thrombocytopenic, Idiopathic

Interventions Eltrombopag Olamine

Updated 6 times since 2017 Last updated: Jul 12, 2018 Started: Jun 30, 2012 Primary completion: Jun 30, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01610180, this PHASE2 trial focuses on Autoimmune Thrombocytopenia and Autoimmune Thrombocytopenic Purpura and remains completed. Sponsored by Fondazione Progetto Ematologia, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Aug 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione Progetto Ematologia

Data source: Fondazione Progetto Ematologia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vicenza, Italy